Abstracts tagged "outcome measures and systemic sclerosis"

Abstract Number: 1876 • 2018 ACR/ARHP Annual Meeting
Machine Learning Classification of Peripheral Blood Gene Expression Identifies a Subset of Patients with Systemic Sclerosis Most Likely to Show Clinical Improvement in Response to Hematopoietic Stem Cell Transplant
Jennifer Franks¹, Viktor Martyanov², Tammara A. Wood², Leslie Crofford³, Lynette Keyes-Elstein⁴, Daniel E. Furst⁵, Ellen Goldmuntz⁶, Maureen D. Mayes⁷, Peter McSweeney⁸, Richard Nash⁸, Keith Sullivan⁹ and Michael L. Whitfield¹⁰, ¹Geisel School of Medicine at Dartmouth, Hanover, NH, ²Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, ³Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN, ⁴Rho, Inc, Chapel Hill, NC, ⁵University of California Los Angeles, Los Angeles, CA, ⁶NIAID, NIH, Bethesda, MD, ⁷Rheumatology, University of Texas McGovern Medical School, Houston, TX, ⁸Colorado Blood Cancer Institute, Denver, CO, ⁹Duke University Medical Center, Durham, NC, ¹⁰Biomedical Data Science, Geisel School of Medicine at Dartmouth, Hanover, NH
Background/Purpose: The SCOT (Scleroderma: Cyclophosphamide or Transplantation) trial (Sullivan K. et al, 2018) demonstrated the clinical benefit of hematopoietic stem cell transplant (HSCT) compared to…
Abstract Number: 726 • 2017 ACR/ARHP Annual Meeting
Performance of the American College of Rheumatology Provisional Composite Response Index in Systemic Sclerosis (CRISS) in the Scleroderma Lung Study-I
Dinesh Khanna¹, Donald P. Tashkin², Holly Wilhalme² and Chi-hong Tseng³, ¹University of Michigan, Ann Arbor, MI, ²University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ³Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: The CRISS has been proposed as a composite outcome measure for trials in systemic sclerosis1. CRISS is a 2-step process that assigns a probability…
Abstract Number: 2662 • 2017 ACR/ARHP Annual Meeting
The EULAR Systemic Sclerosis Impact of Disease (ScleroID) Score – a New Patient-Reported Outcome Measure for Patients with Systemic Sclerosis – Preliminary Results from the Ongoing Validation Study
Rucsandra Dobrota¹, Mike Oliver Becker¹, Kim Fligelstone², Jaap Fransen³, Ann Kennedy⁴, Yannick Allanore⁵, Patricia Carreira⁶, László Czirják⁷, Christopher Denton⁸, Roger Hesselstrand⁹, Gunnel Sandqvist¹⁰, Otylia Kowal-Bielecka¹¹, Marco Matucci-Cerinic¹², Carina Mihai¹³, Ana Maria Gheorghiu¹⁴, Ulf Müller-Ladner¹⁵, MC Vonk¹⁶, Turid Heiberg¹⁷ and Oliver Distler¹⁸, ¹Department of Rheumatology, Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²Royal Free Hospital, Scleroderma Unit and Scleroderma Society, London, United Kingdom, ³Department of Rheumatolgy, Radboud University Medical Center, Nijmegen, Netherlands, ⁴Federation of European Scleroderma Associations (FESCA), Tournai, Belgium, ⁵Department of Rheumatology, Cochin Hospital, Paris Descartes University, Paris, France, ⁶Department of Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, ⁷Department of Rheumatology and Immunology, University of Pécs, Faculty of Medicine, Pécs, Hungary, ⁸Department of Rheumatology, University College London, Royal Free Hospital, London, United Kingdom, ⁹Lund University, Lund, Sweden, ¹⁰Department of Rheumatology, Lund University Hospital, Lund, Sweden, ¹¹Department of Rheumatology and Internal Medicine, Medical University of Białystok, Białystok, Poland, ¹²Dept of Medicine/Div of Rheum, University of Florence, Florence, Italy, ¹³Internal Medicine and Rheumatology Dept., Cantacuzino Clinical Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, ¹⁴Carol Davila University of Medicine and Pharmacy,Internal Medicine and Rheumatology Department ,,Dr.I.Cantacuzino'' Clinical Hospital, Bucharest, Romania, ¹⁵Justus-Liebig-University Giessen, Department of Internal Medicine and Rheumatology, Kerckhoff-Klinik, Bad Nauheim, Germany, Bad-Nauheim, Germany, ¹⁶Rheumatology, Radboud University Medical Centre, Nijmegen, Netherlands, ¹⁷Department of Health and Social Sciences, Oestfold University College, Oslo, Norway, ¹⁸Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland
Background/Purpose: Patient reported outcome measures (PROM) are acknowledged a key role in clinical trials in systemic sclerosis (SSc). Given the unmet need of a validated,…
Abstract Number: 2981 • 2017 ACR/ARHP Annual Meeting
Evaluation of American College of Rheumatology Provisional Composite Response Index in Systemic Sclerosis (CRISS) in the Fasscinate Trial
Dinesh Khanna¹, Veronica J. Berrocal², Christopher Denton³, Angelika Jahreis⁴, Helen Spotswood⁵, Celia J. F. Lin⁴, Jeffrey Siegel⁶ and Daniel E. Furst⁷, ¹University of Michigan, Ann Arbor, MI, ²Div of Rheumatology, University of Michigan, Ann Arbor, MI, ³Department of Rheumatology, University College London, Royal Free Hospital, London, United Kingdom, ⁴Genentech, South San Francisco, CA, ⁵Roche Products Ltd., Welwyn Garden City, CA, United Kingdom, ⁶Roche Products Ltd., Welwyn Garden City, United Kingdom, ⁷University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Treatment with Interleukin-6R inhibitor, tocilizumab (TCZ), in early progressive systemic sclerosis (SSc; the faSScinate trial) resulted in consistent, but not statistically significant, improvements in…
Abstract Number: 2909 • 2016 ACR/ARHP Annual Meeting
Attitudes Toward Patient-Reported Outcome Instruments for the Assessment of Raynaud’s Phenomenon in Systemic Sclerosis
John Pauling^1,2, Tracy M. Frech^3,4, Michael Hughes⁵, Jessica K. Gordon⁶, Robyn T. Domsic⁷, Francesca Ingegnoli⁸, Neil J. McHugh^1,9, Sindhu R. Johnson¹⁰, Marie Hudson¹¹, Francesco Boin¹², Voon Ong¹³, Marco Matucci Cerinic¹⁴, Nezam Altorok¹⁵, Marina Scolnik¹⁶, Mandana Nikpour¹⁷, Ankoor Shah¹⁸, Janet E. Pope¹⁹, Dinesh Khanna²⁰ and Ariane L. Herrick²¹, ¹Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom, ²Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ³Internal Medicine, Salt Lake City VAMC, Salt Lake, UT, ⁴Internal Medicine-Division of Rheumatology, University of Utah School of Medicine, SLC, UT, ⁵Centre for Musculoskeletal Research, The University of Manchester, Manchester, United Kingdom, ⁶Rheumatology, Hospital for Special Surgery, New York, NY, ⁷Medicine - Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh, PA, ⁸Department of Rheumatology, Istituto Gaetano Pini, University of Milano, Italy, Milano, Italy, ⁹Rheumatology, Royal National Hospital for Rheumatic Diseases, Upper Borough Walls, United Kingdom, ¹⁰Medicine, Division of Rheumatology, Toronto Western Hospital, University Health Network Pulmonary Hypertension Programme, Toronto General Hospital, Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada, ¹¹Department of Medicine, McGill University and Jewish General Hospital, Montreal, QC, Canada, ¹²Rheumatology, University California San Francisco, San Francisco, CA, ¹³Rheumatology, University College London Medical School, Royal Free Hospital, London, UK, London, United Kingdom, ¹⁴Department of Medicine, Division of Rheumatology, University of Florence, Italy, Florence, Italy, ¹⁵Rheumatology, University of Toledo Medical Center,, Toledo, OH, ¹⁶Rheumatology Section, Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, ¹⁷Department of Medicine (St Vincent's Hospital), The University of Melbourne, Melbourne, Australia, ¹⁸Rheumatology and Immunology, Duke University Medical Center, Durham, NC, ¹⁹Monsignor Roney Bldg/Rheum, University of Western Ontario, St Joseph Health Care, London, ON, Canada, ²⁰Division of Rheumatology, University of Michigan Medical School, Ann Arbor, MI, ²¹Centre for Musculoskeletal Research, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom
Background/Purpose: The Raynaud’s Condition Score (RCS) diary is a clinician-derived validated patient-reported outcome (PRO) instrument for assessing the frequency, duration and severity of Raynaud's phenomenon…
Abstract Number: 415 • 2015 ACR/ARHP Annual Meeting
Development of a Juvenile Systemic Sclerosis Response Index (JSSRI)
Ivan Foeldvari¹, Gyorgyi Zoltan², Eileen Baildam³, Ezgi Deniz Batu⁴, Michael Blakley⁵, Mustafa Cakan⁶, Megan Curran⁷, Antonia Kienast⁸, Kim Fligelstone⁹, Dana Nemkova¹⁰, Clarissa Pilkington¹¹, Nicolino Ruperto¹², Maria Tsinti¹³, Elena Tsitsami¹⁴, Kristina Urbanvica¹⁵ and Tamas Constantin¹⁶, ¹Hamburger Zentrum für Kinder-und Jugendrheumatologie, Hamburg, Germany, ²Semmelweiss University Budapest, Budapest, Hungary, ³Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom, ⁴Hacettepe University Vasculitis Center (HUVAC), Ankara, Turkey, ⁵Internal Medicine and Pediatrics, Indiana University School of Medicine and Riley Hospital for Children at IU Health, Indianapolis, IN, ⁶Pediatric Rheumatology University Childrens Hospital Istanbul, Istanbul, Turkey, ⁷Pediatric Immunology/Rheum, UCSF, San Francisco, CA, ⁸Hamburg Centre for Pediatric and Adolescent Rheumatology, Hamburg, Germany, ⁹FESCA - Scleroderma parents organisation, UK, United Kingdom, ¹⁰Pediatric Rheumatology Unit, Department of Pediatrics and Adolescent Medicine, General University Hospital in Prague, Prague, Czech Republic, ¹¹Paediatric Rheumatology Department, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, ¹²Pediatrica II, Instituto Giannina Gaslini, PRINTO, Genoa, Italy, ¹³Ped rheum univ child hosp athen, Athena, Greece, ¹⁴First Department of Pediatrics, Athens University Medical School, Athens, Greece, ¹⁵Pediatric Rheumatology, Riga, Latvia, ¹⁶Semmelweis University, Budapest, Hungary
Background/Purpose: Juvenile systemic sclerosis (jSSc) is an orphan disease. We have currently new promising effective medication to treat systemic sclerosis, but no valid outcome measures…
Abstract Number: 2701 • 2014 ACR/ARHP Annual Meeting
Relevance of the 6-Minute Walking Test in Assessing the Severity and Outcome of Pulmonary Arterial Hypertension Associated with Systemic Sclerosis, without Extensive Interstitial Lung Disease
Sébastien Sanges^1,2,3, David Launay^1,2,3, Rennie L. Rhee⁴, Olivier Sitbon^5,6,7, Eric Hachulla^2,3,8, Luc Mouthon⁹, Loïc Guillevin⁹, Laurence Rottat^5,6,7, Pierre Clerson¹⁰, Jean-Francois Cordier¹¹, Steven M. Kawut¹², Gérald Simonneau^5,6,7 and Marc Humbert^5,6,7, ¹Université Lille Nord de France, Faculté de Médecine Henri Warembourg, Lille, Lille, France, ²EA 2686, Lille, Lille, France, ³Service de médecine interne, Centre National de Référence de la Sclérodermie Systémique, Hôpital Claude Huriez, CHRU Lille, Lille, France, ⁴Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁵Université Paris-Sud, Faculté de Médecine, Le Kremlin-Bicêtre, Le Kremlin-Bicêtre, France, ⁶Service de Pneumologie, DHU Thorax Innovation, AP-HP, Hôpital Bicêtre, Le Kremlin-Bicêtre, France, ⁷INSERM U999, Centre Chirurgical Marie-Lannelongue, LabEx LERMIT, Le Plessis-Robinson, Le Plessis-Robinson, France, ⁸Faculté de Médecine Henri Warembourg, Université Lille Nord de France, Lille, France, ⁹National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ¹⁰Orgametrie, Roubaix, France, ¹¹Division of Pneumology, Hôpital Louis-Pradel, Hospices Civils de Lyon, Lyon 1, Lyon, France, ¹²Pulmonary and Critical Care, University of Pennsylvania, Philadelphia, PA
Background/Purpose In pulmonary arterial hypertension (PAH) associated with systemic sclerosis (SSc), no study has yet evaluated the correlation between the 6-minute walking test (6MWT) distance…
Abstract Number: 720 • 2014 ACR/ARHP Annual Meeting
Measures of Disease Status in Systemic Sclerosis: Systematic Review
Tien Tay¹, Nava Ferdowsi¹, Wendy Stevens¹, Marie Hudson², Murray Baron³, Candice Rabusa¹, David Prior⁴, Susanna Proudman⁵ and Mandana Nikpour⁶, ¹Rheumatology, The University of Melbourne at St Vincent’s Hospital, Melbourne, Australia, ²Rheumatology, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada, ³Pavillion A, Rm 216, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada, ⁴Cardiology, The University of Melbourne at St Vincent’s Hospital, Melbourne, Australia, ⁵Royal Adelaide Hospital, Rheumatology Unit and University of Adelaide, Discipline of Medicine, Adelaide, Australia, ⁶Medicine, The University of Melbourne at St Vincent’s Hospital, Melbourne, Australia
Background/Purpose : To identify the measures of disease status in systemic sclerosis (SSc) using a systematic review. Methods: A systematic review of Medline (1966-2014), EMBASE…
Abstract Number: 737 • 2014 ACR/ARHP Annual Meeting
Reliability of Nailfold Capillary Density Measurement As a Possible Outcome Measure for Systemic Sclerosis-Related Microangiopathy
Graham Dinsdale¹, Tonia Moore², Joanne Manning², Andrea Murray¹, Michael Berks³, Philip Tresadern³, Chris Taylor³, Neil O'Leary⁴, Chris Roberts⁴, John Allen⁵, Marina Anderson⁶, Maurizio Cutolo⁷, Roger Hesselstrand⁸, Kevin Howell⁹, Paula Pyrkotsch⁶, Francesca Ravera⁷, Vanessa Smith¹⁰, Alberto Sulli⁷, Marie Wildt⁸ and Ariane Herrick¹, ¹Centre for Musculoskeletal Research, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, ²Salford Royal Hospital NHS Foundation Trust, Salford, United Kingdom, ³Centre for Imaging Sciences, University of Manchester, Institute of Population Health, Manchester, United Kingdom, ⁴Centre for Biostatistics, Institute of Population Health, University of Manchester, Manchester, United Kingdom, ⁵Regional Medical Physics Department, Freeman Hospital, Newcastle upon Tyne, United Kingdom, ⁶Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom, ⁷Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, ⁸Rheumatology, Lund University, Lund, Sweden, ⁹Institute of Immunity and Transplantation, University College London, Royal Free Campus, London, United Kingdom, ¹⁰Department of Rheumatology, Ghent University Hospital, Ghent, Belgium
Background/Purpose Nailfold videocapillaroscopy allows non-invasive assessment of the microcirculation. Image annotation software allows tracking of changes over time; a potential outcome measure for systemic sclerosis…
Abstract Number: 1749 • 2013 ACR/ARHP Annual Meeting
Treatment Strategies and Outcomes In Patients With Systemic Sclerosis and Acute Myocardial Infarction
Priya Prakash¹, Dhaval Kolte¹, Sahil Khera¹, Jagadish Khanagavi¹, Marjan Mujib², Chandrasekar Palaniswamy³, Farrah Gutwein⁴, Sachin Sule¹, Wilbert S. Aronow³, William H. Frishman³ and Julia Ash⁴, ¹Medicine, New York Medical College, Valhalla, NY, ²Internal Medicine, New York Medical College, Valhalla, NY, ³Cardiology, New York Medical College, Valhalla, NY, ⁴Rheumatology, New York Medical College, Valhalla, NY
Background/Purpose: , Systemic Sclerosis (SSc) is associated with an increased risk of cardiovascular diseases, including acute myocardial infarction (AMI). However, whether SSc influences treatment choice and…
Abstract Number: 1484 • 2012 ACR/ARHP Annual Meeting
Investigating Determinants of Subjective and Objective Assessments of Peripheral Vascular Function in Primary Raynaud’s Phenomenon and Systemic Sclerosis
John D. Pauling¹, Jacqueline A. Shipley¹, Nigel Harris² and Neil McHugh², ¹Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom
Background/Purpose: The Raynaud’s condition score (RCS) diary is recommended for use in clinical trials of Raynaud’s phenomenon (RP) and systemic sclerosis (SSc). We report the…
Abstract Number: 717 • 2012 ACR/ARHP Annual Meeting
Results From a Multi-Tiered Item Collection On Linking Systemic Sclerosis to the International Classification of Functioning, Disability and Health: A EULAR Scleroderma Trials and Research Initiative
Lesley Ann Saketkoo¹, Reuben Escorpizo², Kevin J. Keen³, Kim Fligelstone⁴ and Oliver Distler⁵, ¹LSU Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, ²ICF Research Branch in cooperation with the WHO Collaborating Centre for the Family of International Classifications in Germany (DIMDI), Nottwil, Switzerland, ³Mathematics and Statistics, University of Northern British Columbia, Prince George, BC, Canada, ⁴Royal Free Hospital, Scleroderma Unit and Scleroderma Society, London, United Kingdom, ⁵Department of Rheumatology and Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland
Background/Purpose: Systemic Sclerosis (SSc) affects multiple organs with complex combinations of disability. Skin fibrosis, ischemic pain, ulceration, arthritis, joint contractures, myopathy and cardiopulmonary, renal as…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].